| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
4-IPP is a drift suicide substrate of MIF that inhibits MIF's biological action by binding to it covalently and irreversibly [1]. 4-IPP blocks MIF's interaction with the thioredoxin-responsive protein-p65 complex, hence inhibiting RANKL-induced p65 phosphorylation and nuclear translocation [1]. 4-IPP promotes osteocyte-mediated osteoclastogenesis and suppresses NF-κB receptor activator ligand (RANKL)-induced osteoclastogenesis. In a dose-dependent manner, 4-IPP (0.5 - 200 μM; 24-72 hours) suppresses osteoclastogenesis. generation of osteoclasts[1]. 4-IPP (5 – 20 μM); 5[1] mineralizes and forms bones.
|
|---|---|
| ln Vivo |
4-IPP (1 mg/kg, 5 mg/kg; every 2 days; for 8 weeks) increases osteoblastic bone formation and decreases osteoclast activity to improve bone loss related to female food deprivation.[1]
|
| Cell Assay |
Cytotoxicity assay[1]
Cell Types: BMMs Tested Concentrations: 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM , 50 μM, day) inhibits RANKL-induced osteoclast resorption and bone resorption [1]. 100 μM, 200 μM Incubation Duration: 24 hrs (hours), 72 hrs (hours) Experimental Results: Inhibition of osteoclastogenesis in a dose-dependent manner. Western Blot Analysis [1] Cell Types: BMMs Tested Concentrations: 5 μM, 10 μM, 20 μM Incubation Duration: 1 day, 3 days, 5 days Experimental Results: Inhibition of RANKL-induced osteoclast differentiation and bone resorption. |
| Animal Protocol |
Animal/Disease Models: 8weeks old C57BL/6J male mice [1]
Doses: 1 mg/kg, 5 mg/kg Route of Administration: intraperitoneal (ip) injection; once every 2 days; for 8 weeks Experimental Results: Alleviation of OVX-induced osteoporosis . |
| References | |
| Additional Infomation |
4-iodo-6-phenylpyrimidine is a member of the class of pyrimidines carrying iodo and phenyl substituents at positions 4 and 6 respectively. It has a role as a macrophage migration inhibitory factor inhibitor, an antineoplastic agent and an apoptosis inducer. It is a member of pyrimidines, a biaryl and an organoiodine compound.
|
| Molecular Formula |
C10H7IN2
|
|---|---|
| Molecular Weight |
282.08
|
| Exact Mass |
281.965
|
| CAS # |
41270-96-6
|
| PubChem CID |
817368
|
| Appearance |
White to yellow solid powder
|
| Density |
1.728±0.06 g/cm3
|
| Boiling Point |
380.2±30.0 °C
|
| LogP |
2.748
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
13
|
| Complexity |
157
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ZTCJXHNJVLUUMR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H7IN2/c11-10-6-9(12-7-13-10)8-4-2-1-3-5-8/h1-7H
|
| Chemical Name |
4-Iodo-6-phenyl-pyrimidine
|
| Synonyms |
4 IPP 4IPP 4-IPP
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~354.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.86 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.86 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5451 mL | 17.7255 mL | 35.4509 mL | |
| 5 mM | 0.7090 mL | 3.5451 mL | 7.0902 mL | |
| 10 mM | 0.3545 mL | 1.7725 mL | 3.5451 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00924157 | COMPLETED | Dietary Supplement: IPP Other: Placebo |
Coronary Artery Disease | Boston University | 2009-07 | Not Applicable |
| NCT06369870 | RECRUITING | Drug: Levobupivacaine Hydrochloride 0.25 % Injectable Solution Drug: Sodium chloride 0.9% |
Analgesic Effect | Algemeen Ziekenhuis Maria Middelares | 2024-09-01 | Phase 4 |
| NCT00636506 | COMPLETEDWITH RESULTS | Device: AMS 700 IPP with MS Pump | Erectile Dysfunction | American Medical Systems | 2005-08 | Phase 2 |
| NCT06271902 | NOT YET RECRUITING | Other: Singapore Youth Shoulder Overuse Injury Prevention Program Other: Lower body stretching program |
Sport Injury | Nanyang Technological University | 2024-03 | Not Applicable |
| NCT05285215 | RECRUITING | Procedure: Integrated psychological program (IPP) | Depression, Postpartum | KK Women's and Children's Hospital | 2022-04-18 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
